Eli Lilly and Co

Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
47,000
Ticker
LLY
Exchange
NEW YORK STOCK EXCHANGE, INC.
Description
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose...

Eli Lilly and Co's GHG Emissions Data Preview

In 2024, Eli Lilly and Co completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).

However, Eli Lilly and Co has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Market-Based
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Location-Based
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Unspecified Calculation Method
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000

This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into Eli Lilly and Co's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Eli Lilly and Co amounted to 450,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Eli Lilly and Co decreased by 14.61%, showing that the company has made progress in taking action to reduce the climate impact of its operations.

Eli Lilly and Co's Scope 1 Emissions Over Time

2018201920202021202220232024055 k110 k165 k220 ktCO2e-4%-17%-1%+9%+6%+5%
  • Total Scope 1
  • Year-over-Year Change

What are Eli Lilly and Co's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Eli Lilly and Co were 192,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).

Has Eli Lilly and Co reduced its Scope 1 emissions over time?

Since 2018, Eli Lilly and Co's Scope 1 emissions have decreased by 4.48%, reflecting a declining long-term trend in Scope 1 emissions over time.

Compared to the previous year (2023), Eli Lilly and Co's Scope 1 emissions increased by 5.49%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.

What are Eli Lilly and Co's Scope 2 emissions?

In 2024, Eli Lilly and Co reported Scope 2 greenhouse gas (GHG) emissions of 258,000 tCOâ‚‚e using the market-based method.

Has Eli Lilly and Co reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Eli Lilly and Co's Scope 2 emissions (Market-Based) fell by 25.22% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.

What methodology does Eli Lilly and Co use for Scope 2 reporting?

In 2024, Eli Lilly and Co reported its Scope 2 emissions using the market-based method.

Eli Lilly and Co's Scope 2 Emissions Over Time

20182019202020212022202320240200 k400 k600 k800 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based
  • Total Scope 2 (Unspecified Calculation Method)
Want Full Access to Eli Lilly and Co's GHG Emissions Dataset?
Sign Up